M. MAETANI, N. KATO, V. A. P. JABOR, F. A. CALIL, M. C. NONATO, C. A. SCHERER, S. L. SCHREIBER\* (HARVARD UNIVERSITY, BROAD INSTITUTE, AND HOWARD HUGHES MEDICAL INSTITUTE, CAMBRIDGE, USA; UNIVERSITY OF SÃO PAULO, BRAZIL) Discovery of Antimalarial Azetidine-2-carbonitriles that Inhibit *P. falciparum* Dihydroorotate Dehydrogenase *ACS Med. Chem. Lett.* **2017**, *8*, 438–442.

## Synthesis of Dihydroorotate Dehydrogenase Inhibitor BRD9185

**Significance:** Dihydroorotate dehydrogenase (DHODH) is necessary for pyrimidine biosynthesis in protozoan parasites of the genus *Plasmodium*, the causative agents of malaria. BRD9185 is a DHODH inhibitor that has in vitro activity against multidrug-resistant blood-stage parasites (EC $_{50}$  = 0.016  $\mu$ M) and is curative after just three doses in a *P. berghei* mouse model. BRD9185 has a long half-life (15 h) and low clearance in mice.

**Comment:** The key step in the synthesis depicted was the construction of the azetidine-2-carbonitrile core by a 4-exo-tet cyclization of the anion derived from  $\bf D$ . The stereochemistry of the cyclization depended on the base. Treatment of  $\bf D$  with LiHMDS at -50 °C provided the products  $\bf Ea$  and  $\bf Eb$  in a ratio of approximately 15:1 as a separable mixture. Alternatively, exposure of  $\bf D$  to KHMDS at -78 °C gave nearly exclusively  $\bf Eb$  ( $\bf Ea$ /  $\bf Eb$   $\approx$  1:20). The conversion of  $\bf A$  into  $\bf E$  is described in a preceding paper: J. T. Lowe et al. *J. Org. Chem.* **2012**, *77*, 7187.

**SYNFACTS Contributors:** Philip Kocienski Synfacts 2017, 13(07), 0675 Published online: 19.06.2017 **DOI:** 10.1055/s-0036-1590519; **Reg-No.:** K02617SF

Category

Synthesis of Natural Products and Potential Drugs

**Key words** 

**BRD9185** 

dihydroorotate dehydrogenase

azetidine-2carbonitriles

4-exo-tet cyclization

